- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00368901
STAAR-2 Clinical Study
March 4, 2010 updated by: Amgen
A Multicenter Study Using Once Every Other Week Subcutaneous Administration of Aranesp™ (Darbepoetin Alfa) and Iron Guided Algorithms to Treat Subjects With Anemia of Chronic Renal Insufficiency (CRI)
To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
To assess the effect of Aranesp_ on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.
To assess the association between subject self-reported health-related quality of life (HRQoL) as it relates to Hgb concentration and glomerular filtration rate (GFR) in subjects who were rHuEPO-naïve prior to study enrollment.
To characterize the health-related resource utilization of subjects with CRI.
To characterize the subject satisfaction with Aranesp_ compared to previous rHuEPO therapy.
To characterize iron treatment in subjects with CRI.
To assess the safety profile of Aranesp_ therapy in subjects with CRI
Study Type
Interventional
Enrollment (Actual)
618
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥ 18 years old
- diagnosis of CRI and not receiving dialysis therapy (must be predialysis)
- measured or estimated (using the Cockcroft-Gault formula) creatinine clearance (CrCl) of ≤ 70 mL/min, or GFR ≤ 60 mL/min (using the MDRD formula):
- Cockcroft-Gault formula: CrCl = (140 minus age in years) x (body weight in kg) serum creatinine (mg/dL) x 72.0 For women, the value will be multiplied by 0.85
- MDRD formula: GFR = 170 x [SCr]-0.999 x [Age]-0.167 x [0.762 if subject is female] x [1.180 if subject is black] x [sun] -0.170SAlb]-0.318
- mean Hgb < 11 g/dL during the screening/baseline period (if subject is not already receiving rHuEPO therapy)
- for subjects currently receiving rHuEPO therapy, the subject must have: a stable rHuEPO dose for the past month; and a rHuEPO frequency of once weekly.
- white blood cell and platelet counts within normal limits
- serum vitamin B12 and folate levels above the lower limit of normal range
- transferrin saturation (TSAT) ≥ 20% during the screening period
- availability for follow-up assessments
- subject must be able to comprehend and be willing to, or have legally accepted representative, give written informed consent for participation in the study
Exclusion Criteria:
- scheduled to initiate dialysis
- uncontrolled hypertension (diastolic blood pressure > 105 mm Hg or systolic blood pressure of > 180 mm Hg during the screening/baseline period on two separate measurements)
- clinically unstable in the judgment of the investigator (eg, subject is in the intensive care unit, immediately post-myocardial infarction, etc)
- scheduled to receive a living donor kidney transplant
- treatment of grand mal epilepsy within the past 6 months
- moderate to severe congestive heart failure (NYHA class III or IV)
- clinical evidence of severe secondary hyperparathyroidism (parathyroid hormone level > 1500 pg/mL)
- severe active chronic inflammatory process (eg, ulcerative colitis, peptic ulcer disease, rheumatoid arthritis, etc)
- currently receiving antibiotic therapy for systemic infection (enrollment may be postponed until the course of antibiotics has ended)
- known aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 times the upper limit of the normal range on more than one occasion within three months prior to screening
- known positive HIV antibody or hepatitis B surface antigen
- clinical evidence of current malignancy and/or receiving chemotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia
- active bleeding or RBC transfusion within eight weeks of enrollment
- androgen therapy within four weeks before enrollment
- known hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma; hemolytic anemia, etc)
- any condition that is likely to affect subject compliance
- currently or previously (within 30 days) enrolled in investigational device or drug trial(s) or receiving investigational agent(s)
- the exception to this is if the subject was enrolled in another Aranesp™ or rHuEPO protocol
- pregnant or breast feeding women (women of child-bearing potential must be using contraceptive precautions)
- women planning to have a child during the study period
- known hypersensitivity to the active substance or any of the excipients
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
Every other week dosing of Aranesp SC
|
Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean hemoglobin during the evaluation period
Time Frame: 52 weeks
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in hemoglobin throughout the study
Time Frame: 52 weeks
|
52 weeks
|
HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study
Time Frame: 52 weeks
|
52 weeks
|
Health-related resource utilization, measured every 4 weeks, throughout the study
Time Frame: 52 weeks
|
52 weeks
|
Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12
Time Frame: 12 weeks
|
12 weeks
|
Iron requirement (dose, frequency, and route) of subjects during the study
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2002
Primary Completion (Actual)
March 1, 2004
Study Completion (Actual)
May 1, 2004
Study Registration Dates
First Submitted
August 24, 2006
First Submitted That Met QC Criteria
August 25, 2006
First Posted (Estimate)
August 29, 2006
Study Record Updates
Last Update Posted (Estimate)
March 5, 2010
Last Update Submitted That Met QC Criteria
March 4, 2010
Last Verified
March 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20010215
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on Darbepoetin alfa
-
AmgenCompletedAnemia | Non-Myeloid Malignancies
-
University of New MexicoUniversity of UtahCompletedHypoxic-Ischemic Encephalopathy Mild | Neonatal EncephalopathyUnited States
-
The Hospital for Sick ChildrenCompletedKidney Failure, ChronicCanada
-
AmgenCompleted
-
Kyowa Kirin Co., Ltd.Completed
-
AmgenCompletedLymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia